我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

胰高血糖素样肽-1对心血管系统的保护作用

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2018年第3期
页码:
360-363
栏目:
综述
出版日期:
2018-03-25

文章信息/Info

Title:
Protective effects of glucagon-like peptide-1 on cardiovascular system
作者:
孙 闯1; 孙冬冬2; 王海昌1
（第四军医大学：1.唐都医院心血管内科，陕西 西安 710038，2.西京医院心血管内科，陕西 西安 710032）
Author(s):
SUN Chuang1;  SUN Dong-dong2;  WANG Hai-chang1
(1.Department of Cardiology, Tangdu Hospital, Xi’an 710038, Shaanxi, China, 2.Department of Cardiology, Xijing Hospital, Fourth Military University, Xi’an 710032, Shaanxi, China)
关键词:
胰高血糖素样肽-1; 糖尿病; 心血管系统; 血压; 缺血/再灌注损伤
Keywords:
Glucagon-like peptide-1;  Diabetes mellitus;  Cardiovascular system;  blood pressure;  ischemia/reperfusion injury
分类号:
R322.1
DOI:
-
文献标识码:
A
摘要:
胰高血糖素样肽(GLP)-1作为肠促胰岛素家族中的一员，已经在过去10年中被列为新型抗糖尿病药物。近年来，GLP-1因表现出降糖以外的心血管保护作用成为治疗糖尿病心脏病的研究热点。GLP-1可以通过控制血压、改善内皮功能、抗动脉粥样硬化，减轻缺血/再灌注损伤和提高心脏功能，在心血管系统中发挥多重保护作用。
Abstract:
Glucagon-like peptide-1 (GLP-1) is a member of the incretin family and has been introduced as a new class of antidiabetic medications in the past decade. Recent studies demonstrate that GLP-1 bestows cardiovascular protective effects beyond its hypoglycemic effects, which has become a research hotspot in the treatment of diabetic cardiovascular disease. GLP-1 exerts multiple protective effects on cardiovascular system by controlling the blood pressure, improving endothelial functions, inhibiting the formation of atherosclerotic lesions, reducing myocardial ischemia reperfusion injury, and improving heart function.

参考文献/References

[1]Kang YM,Jung CH.Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists[J].Endocrinol Metab(Seoul),2016,31(2):258-274.

[2] Brubaker PL,Manuel Gil-Lozano.Glucagon-like peptide-1:The missing link in the metabolic clock?[J].J Diabetes Investig,2016,7(1):70-75.

[3]Petrie JR,Marso SP,Bain SC,et al.LEADER-4:blood pressure control in patients with type 2 diabetes and high cardiovascular risk:baseline data from the LEADER randomized trial[J].J Hypertens,2016,34(6):1140-1150.

[4]Robinson LE,Holt TA,Rees K,et al.Effects of exenatide and liraglutide on heart rate, blood pressure and body weight:systematic review and meta-analysis[J].BMJ Open,2013,3(1):e001986.

[5]Smits MM,Muskiet MH,Tonneijck L,et al.Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males[J].Br J Clin Pharmacol,2016,81(4):613-620.

[6]Marc Evans,Anja Schweizer,James E. Foley,Blood pressure and fasting lipid changes after 24 weeks treatment with vildagliptin:a pooled analysis in >2,000 previously drug-naive patients with type 2 diabetes mellitus[J].Vasc Health Risk Manag,2016,12(18):337-340.

[7] Aditya Goud,Jixin Zhong,Matthew Peters,et al.GLP-1 Agonists and Blood Pressure:A Review of the Evidence[J].Curr Hypertens Rep,2016,18(2):16.

[8]Song-Tao Tang,Huan Su,Qiu Zhang,et al.Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase[J].Int J Mol Med,2016(7):1558-1566.

[9]Li Ding,Jin Zhang.Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells[J].Acta Pharmacol Sin,2012,33(1):75-81.

[10]Koshal P,Kumar P.Neurochemical modulation involved in the beneficial effect of liraglutide, GLP-1 agonist on PTZ kindling epilepsy-induced comorbidities in mice[J].Mol Cell Biochem,2016,415(1-2):77-87.

[11]Shiraki A,Oyama J,Komoda H,et al.The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells[J].Atherosclerosis,2012,221(2):375-382.

[12]Koska J,Sands M,Burciu C,et al.Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans[J].Diabetes,2015,64(7):2624-2635.

[13]Hong J,Maron DJ,Shirai T,et al.Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions[J].Int J Clin Rheumtol,2015,10(5):365-381.

[14]Kwasniewska M,Kostka T,Jegier A,et al.Regular physical activity and cardiovascular biomarkers in prevention of atherosclerosis in men:a 25-year prospective cohort study[J].BMC Cardiovasc Disord,2016,16(1):65.

[15]Klonoff DC, Buse JB,Nielsen LL,et al.Exenatide effects on diabetes,obesity,cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years[J].Curr Med Res Opin,2008,24(1):275-286.

[16]Bunck MC,Heine RJ,Diamant M,et al.Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition[J].Diabetes Care,2010,33(8):1734-1737.

[17]Rizzo,M,Chandalia M,Patti AM,et al.Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study[J].Cardiovasc Diabetol,2014,13:49.

[18]DeNicola M,Du JF,Wang ZK,et al.Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium[J].Am J Physiol Endocrinol Metab,2014.307(8):e630-e643.

[19]Ihara M,Asanuma H,Yamazaki S,et al.An interaction between glucagon-like peptide-1 and adenosine contributes to cardio protection of a dipeptidyl peptidase 4 inhibitor from myocardial ischemia-reperfusion injury[J].Am J Physiol Heart Circ Physiol,2015,308(10):H1287-H1297.

[20]Hu SY,Zhang Y,Zhu PJ,et al.Liraglutide directly protects cardio myocytes against reperfusion injury possibly via modulation of intracellular calcium homeostasis[J].J Geriatr Cardiol,2017,14(1):57-66.

[21]Chen,WR,Hu SY,Chen YD,et al.Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J].American Heart Journal,2015,170(5):845-854.

[22]Chen WR,Shen XQ,Zhang Y,et al.Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction[J].Endocrine,2016,52(3):516-526.

[23]Nozue T,Yamada M,Tsunoda T,et al.Effects of liraglutide, a glucagon-like peptide-1 analog,on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention[J].Heart Vessels,2016,31(8):1239-1246.

[24]Kato S,Fukui K,Kirigaya H,et al.Inhibition of DPP-4 by alogliptin improves coronary flow reserve and left ventricular systolic function evaluated by phase contrast cine magneticresonance imaging in patients with type 2 diabetes and coronary artery disease[J].Int J Cardiol,2016,223(15):770-775.

[25]Bernink FJ,Timmers L,Diamant M,et al.Effect of additional treatment with Exenatide in patients with an Acute Myocardial Infarction:the EXAMI study[J].Int J Cardiol,2013,167(1):289-290.

[26]Lonborg J,Vejlstrup N,Kelbak H,et al.Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction[J].Eur Heart J,2012,33(12):1491-1499.

备注/Memo

备注/Memo:
收稿日期：2017-03-30.通讯作者：王海昌，主任医师，主要从事冠心病基础及临床研究 Email：wanghc@fmmu.edu.cn 共同通讯作者：孙冬冬，主治医师，博士，主要从事冠心病疾病研究 Email：wintersun3@gmail.com 作者简介：孙闯，硕士生 Email：271418346@qq.com
更新日期/Last Update: 1900-01-01